ONCOZ (ONCOZ) News
Follow ONCOZ (ONCOZ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
OncoZenge AB (publ) (ONCOZ) Issues 1.45M New Shares At SEK 3.00 To Pay Fees And Set Off Loan
OncoZenge resolved two directed share issues totaling 1,452,331 shares at SEK 3.00 to partly pay the rights issue guarantor and to set off a SEK 2.0M bridge loan plus interest, causing about 5.5% dilution.Material Detail
EQUITY | Sep 29, 2026, 04:45 PM UTC
L
OncoZenge AB (publ) (ONCOZ) Registers Rights Issue; BTA Convert Dates Set
OncoZenge’s rights issue is registered; last BTA trading is 2 Oct 2026, record date 6 Oct, and new shares are expected in accounts 8 Oct. The company will receive approximately SEK 30.7M before issue costs.Material Detai
EQUITY | Sep 29, 2026, 12:15 PM UTC
L
OncoZenge (ONCOZ) Rights Issue Subscribed ~92%
OncoZenge said its rights issue concluded at approximately 92% subscription.Material DetailsContext by AI AnalystThis is a financing update, reinforcing the company's ability to raise capital but with a small shortfall.
NEWS | Sep 23, 2026, 02:07 PM UTC
L
OncoZenge: Final Outcome Of Rights Issue
OncoZenge AB (publ) OMXSTO:ONCOZ:Source text for Workspace:Further company coverage
NEWS | Sep 23, 2026, 06:53 AM UTC
M
OncoZenge rights issue ~92% subscribed; raises ~SEK 30.7M
OncoZenge’s rights issue is preliminarily ~92% subscribed: 80% with rights and 12% without. Expected gross proceeds are ~SEK 30.7M, and the Vator Securities AB guarantee is not expected to be utilised.
EQUITY | Sep 18, 2026, 03:18 PM UTC
L
OncoZenge to Present at Investing in Life Science on September 22
The 4th edition of Investing in Life Science takes place on September 22 in Stockholm. Stian Kildal, CEO will present OncoZenge to specialist life science investors and potential strategic partners.Investing in Life Scie
EQUITY | Sep 10, 2026, 07:01 AM UTC
L
OncoZenge UCLA patient study results to be presented at ASTRO
OncoZenge AB (publ) says Dr. Michelle Ann Eala of UCLA Health will present results from the UCLA Patient Engagement Study at the 2026 ASTRO Annual Meeting in Boston on September 28.
EQUITY | Sep 09, 2026, 08:00 AM UTC
L
OncoZenge CMO to present BupiZenge Phase III at Pain Therapeutics Summit
OncoZenge AB said its CMO Marie-Louise Fjällskog will present the Phase III program for BupiZenge™ at the 20th Annual Pain Therapeutics Summit in the San Francisco Bay Area on September 28–29.
EQUITY | Sep 07, 2026, 08:15 AM UTC
L
OncoZenge says investor missed payment deadline for fourth tranche
OncoZenge says an investor missed the payment deadline for the remaining fourth tranche shares.
EQUITY | Aug 31, 2026, 06:10 AM UTC
L
Deadline expires for Sichuan Yangtian Bio-Pharmaceutical fourth tranche payment
Sichuan Yangtian Bio-Pharmaceutical’s fourth tranche payment deadline has expired without full payment.
EQUITY | Aug 28, 2026, 03:40 PM UTC
L
Oncozenge secures SEK 2.0 mln bridge financing
Oncozenge secured SEK 2.0 mln in bridge financing.
EQUITY | Aug 28, 2026, 09:46 AM UTC
L
OncoZenge secures SEK 2.0 million bridge financing ahead of rights issue
OncoZenge secured bridge financing of SEK 2.0 million ahead of a rights issue.
EQUITY | Aug 28, 2026, 09:35 AM UTC
L
OncoZenge (Q2 Review): En route to market — Pivotal study up and running
OncoZenge (Q2 Review): En route to market — Pivotal study up and running
EQUITY | Aug 28, 2026, 09:16 AM UTC
L
ONCOZ investor withholds remaining fourth-tranche payment
An investor withheld the remaining payment for the fourth tranche, creating a short-term liquidity shortfall for ONCOZ.
EQUITY | Aug 27, 2026, 06:15 PM UTC
L
ONCOZ cites European Phase III approval, milestone payments
ONCOZ says European Phase III approval and milestone payments support funding efforts amid rising R&D costs.
EQUITY | Aug 27, 2026, 06:07 AM UTC
L
OncoZenge AB files interim report for Jan 1–Jun 30, 2026
OncoZenge AB released an interim report covering January 1 through June 30, 2026.
EQUITY | Aug 27, 2026, 06:00 AM UTC
L
OncoZenge announces SEK33.3m rights issue
OncoZenge said it has announced a SEK33.3m rights issue, according to TradingView News.
EQUITY | Aug 26, 2026, 09:20 AM UTC